

Enrollment No: _____

Exam Seat No: _____

C.U.SHAH UNIVERSITY

Summer Examination-2017

Subject Name: Drug Regulatory Aspects & IPR

Subject Code: 5PS02DRI2

Branch: M.Pharm (Pharmaceutics, QA)

Semester: 2

Date: 02/05/2017

Time: 02:00 To 05:00

Marks: 70

Instructions:

- (1) Use of Programmable calculator and any other electronic instrument is prohibited.
 - (2) Instructions written on main answer book are strictly to be obeyed.
 - (3) Draw neat diagrams and figures (if necessary) at right places.
 - (4) Assume suitable data if needed.
-

SECTION – I

- Q-1 Define the following terms: (07)**
- | | |
|-------------------------------|---|
| a. Pharmaceutical Equivalents | 1 |
| b. Drug Master File | 1 |
| c. Orange book | 1 |
| d. Bio-equivalence | 1 |
| e. Orphan drug | 1 |
| f. Stability | 1 |
| g. Validation | 1 |
- Q-2 Attempt all questions (14)**
- | | |
|---|---|
| (a) What are the clinical trials? How are they organized as a part of drug discovery? | 7 |
| (b) Explain in brief freedom of information (FOIA). | 7 |
- OR**
- Q-2 Attempt all questions (14)**
- | | |
|---|---|
| (a) Write a note on Post Marketing Surveillance. | 7 |
| (b) Discuss Supplemental New Drug Application with recent examples. | 7 |
- Q-3 Attempt all questions (14)**
- | | |
|---|---|
| (a) Differentiate NDA and ANDA. Explain the concept of PARA I to IV filing. | 7 |
| (b) Define CTD & eCTD. Explain modules of CTD. | 7 |
- OR**
- Q-3 Attempt all questions**
- | | |
|---|---|
| (a) Discuss role of CBER in USFDA. | 7 |
| (b) What is TGA ? Discuss TGA's risk management approach. | 7 |

SECTION – II

- Q-4 Write the full form of following terms: (07)**
- | | |
|---------|---|
| a. EMEA | 1 |
| b. WIPO | 1 |
| c. CDER | 1 |



	d. TRIPS	1
	e. IPR	1
	f. IND	1
	g. NDA	1
Q-5	Attempt all questions	(14)
	(a) Describe the activity regulated by MHRA.	7
	(b) Write a note on Hatch-Waxman Amendments and its impact on Pharmaceutical industry.	7
	OR	
Q-5	Attempt all questions	(14)
	(a) Write a short note on patent drafting.	7
	(b) Describe briefly the FDA Medicare Modernization Act, 2003 .	7
Q-6	Attempt all questions	(14)
	(a) Write the general rules for PCT.	7
	(b) Write a short note on patent licensing.	7
	OR	
Q-6	Attempt all Questions	(14)
	(a) Give brief introduction of ANVISA and enlist various regulations covered by the said agency.	7
	(b) Describe the benefits of IPRs to improve the quality of research work.	7

